AbbVie Presents Results from Several Studies and Clinical Trials Investigating Medicines Across More than 15 Cancers at the 2019 ASCO and EHA Meetings

On May 30, 2019 AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, reported it will present more than 40 data updates across its oncology portfolio during the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting on May 31-June 4, in Chicago, and the European Hematology Association (EHA) (Free EHA Whitepaper) Annual Congress on June 13-16, in Amsterdam (Press release, AbbVie, MAY 30, 2019, View Source [SID1234536684]). The data presentations will span the company’s investigational and approved oncology portfolio medicines in more than 15 different blood and solid tumor cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For the first time, researchers will also present data from the Phase 3 CLL14 study evaluating venetoclax (VENCLEXTA/VENCLYXTO) plus obinutuzumab versus obinutuzumab plus chlorambucil at ASCO (Free ASCO Whitepaper) (abstract #7502). Results from the trial supported the recent FDA approval of this VENCLEXTA chemotherapy-free combination for previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Researchers will also present new, multi-year, long-term data on the use of single-agent ibrutinib (IMBRUVICA) in CLL/SLL at both ASCO (Free ASCO Whitepaper) and EHA (Free EHA Whitepaper) in 2019. Six years of follow-up data evaluating previously treated patients on ibrutinib therapy from the Phase 3 RESONATETM trial (PCYC-1112) will be presented as a poster discussion at ASCO (Free ASCO Whitepaper) (abstract #7510), and more than five years of follow-up for previously untreated patients on ibrutinib therapy from the Phase 3 RESONATE-2TM trial (PCYC-1115/1116) will be presented in an oral session at EHA (Free EHA Whitepaper) (abstract #S107). The RESONATETM trial’s long-term follow-up data presentation was also selected to be featured at the Best of ASCO (Free ASCO Whitepaper) 2019 Meetings, which highlight cutting-edge science and reflect the leading research and strategies in oncology. Following updates earlier this year, the National Comprehensive Cancer Network (NCCN) now recommends ibrutinib (IMBRUVICA) as a preferred regimen for the initial treatment of CLL/SLL and the only Category 1 single-agent regimen for patients without 17p deletion.1

"The data AbbVie is presenting at ASCO (Free ASCO Whitepaper) and EHA (Free EHA Whitepaper) provide a glimpse into the progress we are making collaboratively advancing a diverse pipeline across a broad range of hematologic malignancies and solid tumors," said Neil Gallagher, M.D., Ph.D., vice president, head of global oncology development, AbbVie. "We continue to make progress with first-in-class medicines like ibrutinib and venetoclax that are approved and are being further investigated as potential treatments for several different forms of hematologic malignancies. AbbVie is also advancing a diverse oncology portfolio of investigational drugs with the potential to address unmet needs in other difficult-to-treat cancers."

IMBRUVICA is a once-daily, first-in-class BTK inhibitor that is administered orally, and is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc.

VENCLEXTA is a first-in-class BCL-2 inhibitor being developed by AbbVie and Roche. VENCLEXTA is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.

To learn more about our work in oncology, visit View Source

Presentations include:

Abstract

Presentation Timing

ASCO Annual Meeting

Ibrutinib

Final Analysis From RESONATE: 6-Year Follow-up
in Patients (Pts) With Previously Treated Chronic
Lymphocytic Leukemia or Small Lymphocytic
Lymphoma (CLL/SLL) on Ibrutinib; Barr et al.;
Abstract #7510

Monday, June 3

Poster Session: 8:00 a.m. – 11:00 a.m. CT

Poster Discussion: 11:30 a.m. – 1:00 p.m. CT

Patient-Reported Outcomes (PROs) With
Ibrutinib-Rituximab in Waldenström
Macroglobulinemia (WM): Results From
iNNOVATE; Tedeschi et al.; Abstract #8018

Monday, June 3

Poster Session: 8:00 a.m. – 11:00 a.m. CT

Poster Discussion: 1:15 p.m. – 2:45 p.m. CT

Interim Analysis of Ibrutinib Plus Paclitaxel for
Patients With Advanced Urothelial Carcinoma
Previously Treated With Platinum-Based
Chemotherapy; Castellano et al.; Abstract #4522

Monday, June 3

Poster Session: 1:15 p.m. – 4:15 p.m. CT

Venetoclax

Effect of Fixed-Duration Venetoclax Plus
Obinutuzumab (VenG) on Progression-Free
Survival (PFS), and Rates and Duration of Minimal
Residual Disease Negativity (MRD-) in Previously
Untreated Patients (pts) with Chronic
Lymphocytic Leukemia (CLL) and Comorbidities;
Fischer K, et al.; Abstract #7502

Tuesday, June 4

Oral Session: 9:45 a.m. – 12:45 p.m. CT

Oral Presentation: 10:09 a.m. – 10:21 a.m. CT

Outcomes of Patients with t(11;14) Multiple
Myeloma: An International Myeloma Working
Group (IMWG) Multicenter Study; Durie BG, et al.;
Abstract #8015

Monday, June 3

Poster Session: 8:00 a.m. – 11:00 a.m. CT

Poster Discussion: 1:15 p.m. – 2:45 p.m. CT

Randomized Phase 2 Trial of Venetoclax +
Fulvestrant Versus Fulvestrant in Estrogen
Receptor+, HER2- Locally Advanced or Metastatic
Breast Cancer Following Recurrence or
Progression During or After a CDK4/6 Inhibitor:
VERONICA; Lindeman GJ, et al.; Abstract
#TPS1108

Sunday, June 2

Poster Session: 8:00 a.m. – 11:00 a.m. CT

Veliparib

Veliparib in Combination with
Chemoradiotherapy (CRT) of
Carboplatin/Paclitaxel (C/P) Plus Radiation in
Patients with Stage III Non-Small Cell Lung Cancer
(NSCLC); Kozono DE, et al.; Abstract #8510

Sunday, June 2

Poster Session: 8:00 a.m. – 11:00 a.m. CT

Poster Discussion: 11:15 a.m. – 12:45 p.m. CT

Mivebresib

Results from the First-in-Human Study of
Mivebresib (ABBV-075), a Pan-Inhibitor of
Bromodomain and Extra Terminal Proteins, in
Patients with Relapsed/Refractory Acute Myeloid
Leukemia; Odenike O, et al.; Abstract #7030

Monday, June 3

Poster Session: 8:00 a.m. – 11:00 a.m. CT

Cell Free DNA in Uveal Melanoma: Results from
the First in Human Trial of Mivebresib (ABBV-
075); Patel SP, et al.; Online Publication

Online Publication

Depatux-M

Phase 1/2 Study of Depatuxizumab Mafodotin
(ABT-414) Monotherapy or Combination with
Temozolomide in Japanese Patients with/without
EGFR-Amplified Recurrent Glioblastoma; Narita Y,
et al.; Abstract #2065

Sunday, June 2

Poster Session: 8:00 a.m. – 11:00 a.m. CT

Rova-T

Phase 1 Study on Preliminary Efficacy of
Rovalpituzumab Tesirine in Japanese Patients
with Advanced, Recurrent Small Cell Lung Cancer;
Akamatsu H, et al.; Abstract #8557

Sunday, June 2

Poster Session: 8:00 a.m. – 11:00 a.m. CT

Ph1/2 Study of Rova-T in Combination with
Nivolumab (Nivo) ± Ipilimumab (Ipi) for Patients
(Pts) with 2L+ Extensive-Stage (ED) SCLC;
Malhotra J, et al.; Abstract #8516

Sunday, June 2

Poster Session: 8:00 a.m. – 11:00 a.m. CT

Poster Discussion: 11:15 a.m. – 12:45 p.m. CT

Predictors Associated with Development of
Pleural and Pericardial Effusions in Patients with
Small Cell Lung Cancer Treated with Third-Line
Therapy; Jiang R, et al.; Online Publication

Online Publication

Teslio-V

Results of the Phase 1b Study of ABBV-399
(Telisotuzumab Vedotin; Teliso-V) in Combination
with Erlotinib in Patients with c-Met+ Non-Small Cell
Lung Cancer by EGFR Mutation Status;
Camidge DR, et al.; Abstract #3011

Saturday, June 1

Poster Session: 8:00 a.m. – 11:00 a.m. CT

Poster Discussion: 3:00 p.m. – 4:30 p.m. CT

c-Met Expression and Response to Telisotuzumab
Vedotin (Teliso-V) in Patients with Non-Small Cell
Lung Cancer; Heist RS, et al.; Abstract #9023

Sunday, June 2

Poster Session: 8:00 a.m. – 11:00 a.m. CT

Poster Discussion: 4:30 p.m. – 6:00 p.m. CT

Peripheral Neuropathy Among Patients with
NSCLC Undergoing Chemotherapy; Tyczynski JE,
et al.; Online Publication

Online Publication

ABBV-085

First-in-Human Phase 1 Study of ABBV-085, an
Antibody-Drug Conjugate (ADC) Targeting
LRRC15, in Sarcomas and Other Advanced Solid
Tumors; Demetri GD, et al.; Abstract #3004

Monday, June 3

Oral Session: 8:00 a.m. – 11:00 a.m. CT

Oral Presentation: 9:12 a.m. – 9:24 a.m. CT

ABBV-621

Phase 1, First-In-Human Study of TRAIL Receptor
Agonist Fusion Protein ABBV-621; Ratain MJ, et
al.; Abstract #3013

Saturday, June 1

Poster Session: 8:00 a.m. – 11:00 a.m. CT

Poster Discussion: 3:00 p.m. – 4:30 p.m. CT

ABBV-181

Safety and Efficacy of Anti-PD-1 Inhibitor ABBV-
181 in Lung and Head and Neck Carcinoma;
Italiano A, et al.; Online Publication

Online Publication

EHA Annual Congress

Ibrutinib

Five Year Follow-Up of Patients Receiving
Ibrutinib for First-Line Treatment of Chronic
Lymphocytic Leukemia; Tedeschi A, et al.;
Abstract #S107

Monday, June 14

Oral Session: 11:30 a.m. – 12:45 p.m. CEST

Oral Presentation: 12:00 p.m. – 12:15 p.m. CEST

Patient-Reported Outcomes from the
iNNOVATETM Study: Results of Ibrutinib-Rituximab
in Waldenström Macroglobulinemia (WM);
Tedeschi A, et al.; Abstract #PF614

Monday, June 14

Poster Display: 5:30 p.m. – 7:00 p.m. CEST

Prognostic Testing and Treatment Approaches
Based on Real-World Clinical Experience from an
Interim Analysis of the INFORMCLL Registry of
Patients with Chronic Lymphocytic Leukemia;
Mato AR, et al.; Abstract #PF383

Monday, June 14

Poster Display: 5:30 p.m. – 7:00 p.m. CEST

Venetoclax

A Phase 1b/2 Clinical Study of Targeted IDH1
Inhibition with Ivosidenib in Combination with the
BCL-2 Inhibitor Venetoclax for Patients with IDH1-
mutated (mIDH1) Myeloid Malignancies; DiNardo
CD, et al.; Abstract #PF291

Friday, June 14

Poster Session: 5:30 p.m. – 7:00 p.m. CEST

Factors Impacting Treatment Selection in
Treatment-Naïve Patients with CLL: A Multicenter
Study; Rhodes J, et al.; Abstract #PF381

Friday, June 14

Poster Session: 5:30 p.m. – 7:00 p.m. CEST

Venetoclax for Chronic Lymphocytic Leukemia: A
Retrospective Chart Review of Safety and Efficacy
From Preapproval Cohort Programs in the
European Union; Schuh, et al.; Abstract #PS1165

Saturday, June 15

Poster Session: 5:30 p.m. – 7:00 p.m. CEST

Venetoclax Alone or in Combination with
Rituximab for Japanese Patients with
Relapsed/Refractory Chronic Lymphocytic
Leukemia; Yamamoto K, et al.; Abstract #PB1890

Online Publication

Efficacy and Safety of Ibrutinib in
Relapsed/Refractory Chronic Lymphocytic
Leukemia in Patients Previously Treated with
Venetoclax in the MURANO Study; Greil R, et al.;
Abstract #PS1161

Saturday, June 15

Poster Session: 5:30 p.m. – 7:00 p.m. CEST

Impact of Major Genomic Alterations on Outcome
of Relapsed/Refractory (R/R) Chronic Lymphocytic
Leukemia (CLL) Patients (Pts) Treated With
Venetoclax Plus Rituximab (Venr) in the Phase 3
MURANO Study; Wu J, et al.; Abstract #PS1123

Saturday, June 15

Poster Session: 5:30 p.m. – 7:00 p.m. CEST

Genetic Markers and Outcome in the CLL14 Trial
of the GCLLSG Comparing Front Line
Obinutuzumab Plus Chlorambucil or Venetoclax in
Patients with Comorbidity; Tausch E, et al.;
Abstract #S105

Friday, June 14

Oral Presentation: 11:30 a.m. – 11:45 a.m. CEST

Updated Safety and Efficacy From a Phase 2
Study of Venetoclax Plus Carfilzomib and
Dexamethasone in Patients with
Relapsed/Refractory Multiple Myeloma; Costa LJ,
et al.; Abstract #PS1375

Saturday, June 15

Poster Session: 5:30 p.m. – 7:00 p.m. CEST

Improved Outcome in Patients With BCL2-Positive
Diffuse Large B-Cell Lymphoma Treated With
Venetoclax Plus R-Chop: Results From the Phase 2
CAVALLI Study; Morschhauser F, et al.; Abstract
#PF294

Friday, June 14

Poster Session: 5:30 p.m. – 7:00 p.m. CEST

Mivebresib

Results From the First-In-Human Study of
Mivebresib (Abbv-075), a Pan-Inhibitor of
Bromodomain and Extra Terminal Proteins, in
Patients With Relapsed/Refractory Acute Myeloid
Leukemia; Borthakur G, et al.; Abstract #PF254

Friday, June 14

Poster Session: 5:30 p.m. – 7:00 p.m. CEST

Navitoclax

Combination BCL-2 Inhibitor Therapy With
Venetoclax (Ven) and Navitoclax (Nav) in Patients
with Relapsed/Refractory (R/R) Acute
Lymphoblastic Leukemia (ALL) and Lymphoblastic
Lymphoma (LL); Pullarkat V, et al.; Abstract
#PS940

Saturday, June 15

Poster Session: 5:30 p.m. – 7:00 p.m. CEST

Additional Research

Outcomes Of Patients With t(11;14) Multiple
Myeloma: An International Myeloma Working
Group Multicenter Study; Kumar S, et al.; Abstract
#PF564

Friday, June 14

Poster Session: 5:30 p.m. – 7:00 p.m. CEST

Longitudinal Treatment Patterns and Patient
Characteristics Among Individuals Diagnosed
With CLL in Israel; Weil C, et al.; Abstract #PS1166

Saturday, June 15

Poster Session: 5:30 p.m. – 7:00 p.m. CEST

Patient Characteristics, Transplant Frequency,
and Treatments in Multiple Myeloma; Karve S, et
al.; Abstract #PF724

Friday, June 14

Poster Session: 5:30 p.m. – 7:00 p.m. CEST

About VENCLEXTA/VENCLYXTO (venetoclax)

VENCLEXTA/VENCLYXTO (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis. VENCLEXTA/VENCLYXTO targets the BCL-2 protein and works to help restore the process of apoptosis.2

VENCLEXTA/VENCLYXTO is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, the companies are committed to BCL-2 research and to studying venetoclax in clinical trials across several blood and other cancers.

VENCLEXTA/VENCLYXTO is approved in more than 50 countries, including the U.S. AbbVie, in collaboration with Roche, is currently working with regulatory agencies around the world to bring this medicine to additional eligible patients in need. Venetoclax is not approved by any regulatory authority, in any country for the treatment of multiple myeloma.

Uses and Important VENCLEXTA (venetoclax) U.S. Safety Information2

Use
VENCLEXTA is a prescription medicine used:

to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
in combination with azacytidine, or decitabine, or low-dose cytarabine to treat adults with newly-diagnosed acute myeloid leukemia (AML) who:
are 75 years of age or older, or
have other medical conditions that prevent the use of standard chemotherapy.
It is not known if VENCLEXTA is safe and effective in children.

What is the most important information I should know about VENCLEXTA?

VENCLEXTA can cause serious side effects, including:
Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure, the need for dialysis treatment, and may lead to death. Your healthcare provider will do tests to check your risk of getting TLS before you start taking VENCLEXTA. You will receive other medicines before starting and during treatment with VENCLEXTA to help reduce your risk of TLS. You may also need to receive intravenous (IV) fluids into your vein. Your healthcare provider will do blood tests to check for TLS when you first start treatment and during treatment with VENCLEXTA. It is important to keep your appointments for blood tests. Tell your healthcare provider right away if you have any symptoms of TLS during treatment with VENCLEXTA, including fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark or cloudy urine, unusual tiredness, or muscle or joint pain.

Drink plenty of water during treatment with VENCLEXTA to help reduce your risk of getting TLS. Drink 6 to 8 glasses (about 56 ounces total) of water each day, starting 2 days before your first dose, on the day of your first dose of VENCLEXTA, and each time your dose is increased.

Your healthcare provider may delay, decrease your dose, or stop treatment with VENCLEXTA if you have side effects.

Who should not take VENCLEXTA?

Certain medicines must not be taken when you first start taking VENCLEXTA and while your dose is being slowly increased because of the risk of increased TLS.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VENCLEXTA and other medicines may affect each other causing serious side effects.
Do not start new medicines during treatment with VENCLEXTA without first talking with your healthcare provider.
Before taking VENCLEXTA, tell your healthcare provider about all of your medical conditions, including if you:

have kidney problems.
have problems with your body salts or electrolytes, such as potassium, phosphorus, or calcium.
have a history of high uric acid levels in your blood or gout.
are scheduled to receive a vaccine. You should not receive a "live vaccine" before, during, or after treatment with VENCLEXTA, until your healthcare provider tells you it is okay. If you are not sure about the type of immunization or vaccine, ask your healthcare provider. These vaccines may not be safe or may not work as well during treatment with VENCLEXTA.
are pregnant or plan to become pregnant. VENCLEXTA may harm your unborn baby. If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with VENCLEXTA, and you should use effective birth control during treatment and for at least 30 days after the last dose of VENCLEXTA. If you become pregnant or think you are pregnant, tell your healthcare provider right away.
are breastfeeding or plan to breastfeed. It is not known if VENCLEXTA passes into your breast milk. Do not breastfeed during treatment with VENCLEXTA.
What should I avoid while taking VENCLEXTA?

You should not drink grapefruit juice or eat grapefruit, Seville oranges (often used in marmalades), or starfruit while you are taking VENCLEXTA. These products may increase the amount of VENCLEXTA in your blood.

What are the possible side effects of VENCLEXTA?

VENCLEXTA can cause serious side effects, including:

Low white blood cell counts (neutropenia). Low white blood cell counts are common with VENCLEXTA, but can also be severe. Your healthcare provider will do blood tests to check your blood counts during treatment with VENCLEXTA.
Infections. Death and serious infections such as pneumonia and blood infection (sepsis) have happened during treatment with VENCLEXTA. Your healthcare provider will closely monitor and treat you right away if you have a fever or any signs of infection during treatment with VENCLEXTA.
Tell your healthcare provider right away if you have a fever or any signs of an infection during treatment with VENCLEXTA.

The most common side effects of VENCLEXTA when used in combination with obinutuzumab or rituximab or alone in people with CLL or SLL include low white blood cell counts; low platelet counts; low red blood cell counts; diarrhea; nausea; upper respiratory tract infection; cough; muscle and joint pain; tiredness; and swelling of your arms, legs, hands, and feet.

The most common side effects of VENCLEXTA in combination with azacitidine or decitabine or low-dose cytarabine in people with AML include low white blood cell counts; nausea; diarrhea; low platelet counts; constipation; fever with low white blood cell counts; low red blood cell counts; infection in blood; rash; dizziness; low blood pressure; fever; swelling of your arms, legs, hands, and feet; vomiting; tiredness; shortness of breath; bleeding; infection in lung; stomach (abdominal) pain; pain in muscles or back; cough; and sore throat.

VENCLEXTA may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of VENCLEXTA. For more information, ask your healthcare provider or pharmacist.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit View Source or call 1-800-FDA-1088.

If you cannot afford your medication, contact www.pparx.org for assistance.

Please see full Prescribing Information, including Medication Guide.

Important VENCLYXTO (venetoclax) EU Safety Information3

VENCLYXTO (venetoclax) Indication
Venclyxto in combination with rituximab is indicated for the treatment of adult patients with chronic lymphocytic leukaemia(CLL) who have received at least one prior therapy.

Venclyxto monotherapy is indicated for the treatment of CLL:

in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor, or
in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemo immunotherapy and a B-cell receptor pathway inhibitor.
Contraindications
Hypersensitivity to the active substance or to any of the excipients is contraindicated. Concomitant use of strong CYP3A inhibitors at initiation and during the dose-titration phase due to increased risk for tumor lysis syndrome (TLS). Concomitant use of preparations containing St. John’s wort as VENCLYXTO efficacy may be reduced.

Special Warnings & Precautions for Use
Tumor lysis syndrome (TLS), including fatal events, has occurred in patients with previously treated CLL with high tumor burden when treated with VENCLYXTO. VENCLYXTO poses a risk for TLS in the initial 5-week dose-titration phase. Changes in electrolytes consistent with TLS that require prompt management can occur as early as 6 to 8 hours following the first dose of VENCLYXTO and at each dose increase. Patients should be assessed for risk and should receive appropriate prophylaxis, monitoring, and management for TLS.

Neutropenia (grade 3 or 4) has been reported and complete blood counts should be monitored throughout the treatment period. Serious infections including events of sepsis with fatal outcome have been reported. Supportive measures including antimicrobials for any signs of infection should be considered.

Live vaccines should not be administered during treatment or thereafter until B-cell recovery.

Drug Interactions
CYP3A inhibitors may increase VENCLYXTO plasma concentrations. At initiation and dose-titration phase: Strong CYP3A inhibitors are contraindicated due to increased risk for TLS and moderate CYP3A inhibitors should be avoided. If moderate CYP3A inhibitors must be used, physicians should refer to the SmPC for dose adjustment recommendations. At steady daily dose: If moderate or strong CYP3A inhibitors must be used, physicians should refer to the SmPC for dose adjustment recommendations.

Avoid concomitant use of P-gp and BCRP inhibitors at initiation and during the dose titration phase.

CYP3A4 inducers may decrease VENCLYXTO plasma concentrations. Avoid coadministration with strong or moderate CYP3A inducers. These agents may decrease venetoclax plasma concentrations.

Co-administration of bile acid sequestrants with VENCLYXTO is not recommended as this may reduce the absorption of VENCLYXTO.

Adverse Reactions
The most commonly occurring adverse reactions (>=20%) of any grade in patients receiving venetoclax in the combination study with rituximab were neutropenia, diarrhea, and upper respiratory tract infection. In the monotherapy studies, the most common adverse reactions were neutropenia/neutrophil count decreased, diarrhea, nausea, anemia, fatigue, and upper respiratory tract infection.

The most frequently occurring serious adverse reactions (>=2%) in patients receiving venetoclax in combination with rituximab or as monotherapy were pneumonia, febrile neutropenia and TLS.

Discontinuation due to adverse reactions occurred in 16% of patients receiving venetoclax plus rituximab and 9% receiving venetoclax monotherapy. Dosage adjustments due to adverse reactions occurred in 15% of patients receiving venetoclax plus rituximab and 2% receiving venetoclax monotherapy. Dose interruptions occurred in 71% of patients treated with the combination of venetoclax and rituximab.

Specific Populations
Patients with reduced renal function (CrCl <80 mL/min) may require more intensive prophylaxis and monitoring to reduce the risk of TLS. Safety in patients with severe renal impairment (CrCl <30 mL/min) or on dialysis has not been established, and a recommended dose for these patients has not been determined. VENCLYXTO should be administered to patients with severe renal impairment only if the benefit outweighs the risk and patients should be monitored closely for signs of toxicity due to increased risk of TLS.

VENCLYXTO may cause embryo-fetal harm when administered to a pregnant woman. Advise nursing women to discontinue breastfeeding during treatment.

Replimune to Present at Upcoming Investor Conferences

On May 30, 2019 Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, reported that members of its senior management team, will present and host investor meetings at the following two conferences (Press release, Replimune, MAY 30, 2019, View Source [SID1234536680]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies 2019 Global Healthcare Conference
Date: Wednesday, June 5, 2019
Presentation Time: 11:30 AM ET
Location: Grand Hyatt, New York, NY

BMO 2019 Prescriptions for Success Healthcare Conference
Date: Tuesday, June 25, 2019
Presentation Time: 11:40 AM ET
Location: Mandarin Oriental, New York, NY

ImaginAb to Present at Upcoming Investor and Scientific Conferences in May and June 2019

On May 30, 2019 ImaginAb, Inc., a clinical stage immuno-oncology imaging company, reported that it is scheduled to present at the following investor and scientific conferences in May and June 2019 (Press release, ImaginAb, MAY 30, 2019, View Source [SID1234536679]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

US-China Bio-Partnering Forum

May 30-31 2019, Chicago, Illinois

Ian Wilson CEO will update investors on current progress of ImaginAb programs and pharmaceutical collaborations.

2019 ASCO (Free ASCO Whitepaper) Annual Meeting

May 31-June 4, 2019, McCormick Place, Chicago, Illinois

Ian Wilson, CEO, Ivan Plavec, CBO, and Ron Korn CMO, will be attending and hosting meetings.

2019 BIO International Convention

June 3-6, 2019, Pennsylvania Convention Center, Philadelphia, Pennsylvania

Ivan Plavec, CBO, will be attending and hosting meetings.

Cavendish Global Conference

June 18-19, 2019, Chicago, Illinois

Ian Wilson CEO will update the conference on current progress of ImaginAb programs and pharmaceutical collaborations.

SNMMI 2019 Annual Meeting

June 22-25, 2019, Anaheim Convention Center, Anaheim, California

ImaginAb will have a booth at the SNMMI conference, where ImaginAb team will be hosting meetings, with clinical investigators, pharmaceutical companies, and partner organizations.

Ian Wilson CEO will update the conference on ImaginAb’s lead program 89ZrCD8PET on Sunday, June 23 in 6.23 CMIT in the Emerging Technologies session.

Inquiries or to schedule a meeting:

ImaginAb

Ian Wilson, Salli Walker
Email: [email protected]
Phone: +1 310 645 1211

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Manel Mateus
Email: [email protected]
Phone: +44 20 3950 9144

U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA® (gilteritinib)

On May 30, 2019 Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. "Astellas") reported that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. product labeling for XOSPATA (gilteritinib) to include final analysis data from the ADMIRAL trial (Press release, Astellas Pharma, MAY 30, 2019, View Source [SID1234536678]). The data demonstrated improvement in Overall Survival in those treated with gilteritinib monotherapy versus salvage chemotherapy in adult patients with relapsed (disease that has returned) or refractory (resistant to treatment) Acute Myeloid Leukemia (AML) with an FMS-like tyrosine kinase 3 (FLT3) mutation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The ADMIRAL trial’s Overall Survival (OS) findings are encouraging for patients and families impacted by relapsed/refractory FLT3 mutation-positive AML," said Alexander Perl, M.D., Abramson Cancer Center, University of Pennsylvania. "The data underscore the importance of single-agent XOSPATA for this patient population that, until recently, had few remaining treatment options."

Results from the ADMIRAL trial show the median OS for patients who received XOSPATA was 9.3 months compared to 5.6 months for patients who received salvage chemotherapy (Hazard Ratio = 0.64 (95% CI 0.49, 0.83), P=0.0004). The other co-primary endpoints of Complete Remission (CR)/Complete Remission with Partial Hematologic Recovery (CRh) in the XOSPATA arm at the interim analysis was 21% (95% CI: 14.5, 28.8).1

The safety profile of XOSPATA is based on 319 patients with relapsed or refractory AML in three clinical trials (NCT02421939, NCT02014558, and NCT02181660). Fatal adverse reactions occurred in 2% of patients receiving XOSPATA. These included cardiac arrest (1%) and one case each of differentiation syndrome and pancreatitis. The most frequent (≥5%) nonhematological serious adverse reactions reported in patients were fever (13%), dyspnea (9%), renal impairment (8%), transaminase increased (6%) and noninfectious diarrhea (5%). The most frequent (≥5%) grade ≥3 nonhematological adverse reactions reported in patients were transaminase increased (21%), dyspnea (12%), hypotension (7%), mucositis (7%), myalgia/arthralgia (7%), and fatigue/malaise (6%).

Please see Important Safety Information including BOXED WARNING at the end of this press release.

"Delivering innovation and value to address the unmet medical needs of patients is at the core of everything we do," said Bernhardt G. Zeiher, M.D., Chief Medical Officer, Astellas. "The FDA’s approval of the sNDA based on Overall Survival data further highlights the strong potential XOSPATA has to help patients suffering from FLT3 mutation-positive AML, a life-threatening disease."

The initial approval of XOSPATA in November 2018 by the FDA was based on an interim analysis of the following endpoints in the ADMIRAL clinical trial: the rate of complete remission (CR)/complete remission with partial hematologic recovery (CRh); the duration of CR/CRh (DOR); and the rate of conversion from transfusion dependence to transfusion independence.

The FDA reviewed the sNDA for XOSPATA under the Oncology Center of Excellence Real-Time Oncology Review pilot program, which aims to explore a more efficient review process by allowing the FDA to evaluate clinical data as soon as trial results become available.

XOSPATA was discovered through a research collaboration with Kotobuki Pharmaceutical Co., Ltd., and Astellas has exclusive global rights to develop, manufacture and commercialize XOSPATA.

XOSPATA was approved by the Japan Ministry of Health, Labor and Welfare (MHLW) for relapsed or refractory AML with FLT3 mutations and launched as XOSPATA 40 mg Tablets in 2018.2 In February 2019, the European Medicines Agency accepted a marketing authorization application (MAA) for regulatory review. The MAA is for the oral once-daily therapy XOSPATA for the treatment of adult patients who have relapsed or refractory AML with a FLT3 mutation.3

Astellas is currently investigating gilteritinib in various FLT3 mutation-positive AML patient populations through several Phase 3 trials. Visit View Source to learn more about ongoing gilteritinib clinical trials.

About the ADMIRAL Trial4
The Phase 3 ADMIRAL trial (NCT02421939) was an open-label, multicenter, randomized study of gilteritinib versus salvage chemotherapy in adult patients with FLT3 mutations who are refractory to, or have relapsed after, first-line AML therapy. The co-primary endpoints of the trial were Overall Survival and Complete Remission (CR)/Complete Remission with Partial Hematologic Recovery (CRh). The study enrolled 371 patients with relapsed or refractory AML and positive for FLT3 mutations present in bone marrow or whole blood. Subjects were randomized in a 2:1 ratio to receive gilteritinib (120 mg) or salvage chemotherapy.

About XOSPATA (gilteritinib)
XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory Acute Myeloid Leukemia (AML) with an FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.1

Important Safety Information

Contraindications
XOSPATA is contraindicated in patients with hypersensitivity to gilteritinib or any of the excipients. Anaphylactic reactions have been observed in clinical trials.

WARNING: DIFFERENTIATION SYNDROME

Patients treated with XOSPATA have experienced symptoms of differentiation syndrome, which can be fatal or life-threatening if not treated. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, or renal dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.

Warnings and Precautions

Differentiation Syndrome (See BOXED WARNING) 3% of 319 patients treated with XOSPATA in the clinical trials experienced differentiation syndrome. Differentiation syndrome is associated with rapid proliferation and differentiation of myeloid cells and may be life-threatening or fatal if not treated. Symptoms of differentiation syndrome in patients treated with XOSPATA included fever, dyspnea, pleural effusion, pericardial effusion, pulmonary edema, hypotension, rapid weight gain, peripheral edema, rash, and renal dysfunction. Some cases had concomitant acute febrile neutrophilic dermatosis. Differentiation syndrome occurred as early as 2 days and up to 75 days after XOSPATA initiation and has been observed with or without concomitant leukocytosis. If differentiation syndrome is suspected, initiate dexamethasone 10 mg IV every 12 hours (or an equivalent dose of an alternative oral or IV corticosteroid) and hemodynamic monitoring until improvement. Taper corticosteroids after resolution of symptoms and administer corticosteroids for a minimum of 3 days. Symptoms of differentiation syndrome may recur with premature discontinuation of corticosteroid treatment. If severe signs and/or symptoms persist for more than 48 hours after initiation of corticosteroids, interrupt XOSPATA until signs and symptoms are no longer severe.

Posterior Reversible Encephalopathy Syndrome (PRES) 1% of 319 patients treated with XOSPATA in the clinical trials experienced posterior reversible encephalopathy syndrome (PRES) with symptoms including seizure and altered mental status. Symptoms have resolved after discontinuation of XOSPATA. A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic resonance imaging (MRI). Discontinue XOSPATA in patients who develop PRES.

Prolonged QT Interval XOSPATA has been associated with prolonged cardiac ventricular repolarization (QT interval). 1% of the 317 patients with a post-baseline QTc measurement on treatment with XOSPATA in the clinical trial were found to have a QTc interval greater than 500 msec and 7% of patients had an increase from baseline QTc greater than 60 msec. Perform electrocardiogram (ECG) prior to initiation of treatment with XOSPATA, on days 8 and 15 of cycle 1, and prior to the start of the next two subsequent cycles. Interrupt and reduce XOSPATA dosage in patients who have a QTcF >500 msec. Hypokalemia or hypomagnesemia may increase the QT prolongation risk. Correct hypokalemia or hypomagnesemia prior to and during XOSPATA administration.

Pancreatitis 4% of 319 patients treated with XOSPATA in the clinical trials experienced pancreatitis. Evaluate patients who develop signs and symptoms of pancreatitis. Interrupt and reduce the dose of XOSPATA in patients who develop pancreatitis.

Embryo-Fetal Toxicity XOSPATA can cause embryo-fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with XOSPATA and for at least 6 months after the last dose of XOSPATA. Advise males with female partners of reproductive potential to use effective contraception during treatment with XOSPATA and for at least 4 months after the last dose of XOSPATA. Pregnant women, patients becoming pregnant while receiving XOSPATA or male patients with pregnant female partners should be apprised of the potential risk to the fetus.

Adverse Reactions

Fatal adverse reactions occurred in 2% of patients receiving XOSPATA. These were cardiac arrest (1%) and one case each of differentiation syndrome and pancreatitis. The most frequent (≥5%) nonhematological serious adverse reactions reported in patients were fever (13%), dyspnea (9%), renal impairment (8%), transaminase increased (6%) and noninfectious diarrhea (5%).

7% discontinued XOSPATA treatment permanently due to an adverse reaction. The most common (>1%) adverse reactions leading to discontinuation were aspartate aminotransferase increased (2%) and alanine aminotransferase increased (2%).

The most frequent (≥5%) grade ≥3 nonhematological adverse reactions reported in patients were transaminase increased (21%), dyspnea (12%), hypotension (7%), mucositis (7%), myalgia/arthralgia (7%), and fatigue/malaise (6%).

Other clinically significant adverse reactions occurring in ≤10% of patients included: electrocardiogram QT prolonged (9%), hypersensitivity (8%), pancreatitis (5%), cardiac failure (4%), pericardial effusion (4%), acute febrile neutrophilic dermatosis (3%), differentiation syndrome (3%), pericarditis/myocarditis (2%), large intestine perforation (1%), and posterior reversible encephalopathy syndrome (1%).

Lab Abnormalities Shifts to grades 3-4 nonhematologic laboratory abnormalities in XOSPATA treated patients included phosphate decreased (14%), alanine aminotransferase increased (13%), sodium decreased (12%), aspartate aminotransferase increased (10%), calcium decreased (6%), creatine kinase increased (6%), triglycerides increased (6%), creatinine increased (3%), and alkaline phosphatase increased (2%).

Drug Interactions
Combined P-gp and Strong CYP3A Inducers Concomitant use of XOSPATA with a combined P-gp and strong CYP3A inducer decreases XOSPATA exposure which may decrease XOSPATA efficacy. Avoid concomitant use of XOSPATA with combined P-gp and strong CYP3A inducers.

Strong CYP3A inhibitors Concomitant use of XOSPATA with a strong CYP3A inhibitor increases XOSPATA exposure. Consider alternative therapies that are not strong CYP3A inhibitors. If the concomitant use of these inhibitors is considered essential for the care of the patient, monitor patient more frequently for XOSPATA adverse reactions. Interrupt and reduce XOSPATA dosage in patients with serious or life-threatening toxicity.

Drugs that Target 5HT2B Receptor or Sigma Nonspecific Receptor Concomitant use of XOSPATA may reduce the effects of drugs that target the 5HT2B receptor or the sigma nonspecific receptor (e.g., escitalopram, fluoxetine, sertraline). Avoid concomitant use of these drugs with XOSPATA unless their use is considered essential for the care of the patient.

Specific Populations
Lactation: Advise women not to breastfeed during treatment with XOSPATA and for 2 months after the last dose.

PureTech Health to Present at Jefferies 2019 Healthcare Conference

On May 30, 2019 PureTech Health plc (LSE: PRTC) ("PureTech Health"), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, reported that Daphne Zohar, founder and chief executive officer, will present at the Jefferies 2019 Healthcare Conference in New York City on Wednesday, June 5, at 11:30 AM EDT (Press release, PureTech Health, MAY 30, 2019, View Source [SID1234536669]). A webcast of the presentation will be available at View Source under the Reports and Presentations tab.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!